Bupivacaine Effectiveness and Safety in SABER® Trial

Inclusion Criteria: * Patients must be able to read and understand the consent form, provide written consent, complete trial-related procedures, and communicate with the trial staff * Males and females, 18 years of age and older scheduled to undergo elective general abdominal surgery * Patients must be healthy or have only mild systemic disease * BMI \< 45 * Patients must have ECG wave form within normal limits * Female and male patients must agree to use medically acceptable method of contraception throughout the entire trial period and for 1 week after the trial participation is completed Exclusion Criteria: * Patients who are pregnant or lactating * Patients undergoing emergency surgery (unless full consent is obtained and all screening procedures are completed prior to surgery) * Significant concomitant surgical procedure * History of multiple prior laparotomy procedures * Cancer with known metastases pre-operatively, which are suspected to impact post-operative recovery or pain * Planned formation of stoma during surgery or plans to undergo another laparotomy procedure within 30 days post-operatively * Pre-operative evidence of sepsis or septic shock * Pre-operative evaluation that suggests a surgery may preclude full closure of the incision(s) * Patients with current or regular use of systemic steroids, anticonvulsants, antiepileptics, antidepressants, or monoamine oxidase inhibitors, who cannot be withdrawn from these medications * Patients with current or regular use of drugs known to significantly prolong the QTc interval * Patients with known hypersensitivity to local anesthetic agents of the amide type (e.g. lidocaine, bupivacaine) * Patients with known hypersensitivity to morphine * Patients with conditions contraindicated for use of opioids * Patients with atrial fibrillation/flutter or other non-sinus rhythm (including paced rhythm); left bundle branch block (LBBB); or the following conditions: right bundle branch block (RBBB) in presence of a cardiac disease, significant cardiomyopathy, and myocardial infarction within last 6 months * Patients with a serum creatinine level two times more than the local laboratory normal limit * Patients who have received greater than 600 mg morphine equivalent daily dose for three or more days per week in the month prior to the surgical procedure * Patients who are currently being treated with methadone, or history of methadone use within the previous 6 months * Patients with known or suspected abuse of opioids or other illicit drugs * Patients with known or suspected alcohol abuse * Participation in another clinical trial at the same time or within 30 days of this trial * Patients who, in the Investigator's opinion, should not participate in the trial or may not be capable of following the trial schedule for any reason